頁籤選單縮合
| 題 名 | 癌症突發性疼痛用藥之探討=Cancer Breakthrough Pain Therapy |
|---|---|
| 作 者 | 周心怡; 鄭吉元; 陳琦華; | 書刊名 | 藥學雜誌 |
| 卷 期 | 32:2=127 2016.06[民105.06] |
| 頁 次 | 頁17-21 |
| 分類號 | 418.224 |
| 關鍵詞 | 突發性疼痛; 鴉片類止痛藥; Breakthrough pain; Opioid analgesics; Fentanyl buccal film; Oxycodone; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 癌症突發性疼痛是癌症病人在使用止痛藥物治療後已呈穩定狀態,卻又出現短暫性 強烈之疼痛感。突發性癌痛之臨床特徵包括了發作快速、疼痛強烈及持續時間短。依據 突發性癌痛的特性,鴉片類止痛藥為治療之首選。在台灣,fentanyl 口頰溶片 (fentanyl buccal film, Painkyl) 是目前唯一上市用來治療突發性癌痛的藥物。此外,oxycodone 口 服短效劑型 (OxyNorm) 也已取得台灣藥物許可證,不久後即將上市。鴉片類藥物治療具 有相當大的個體差異性,因此在做劑量調整時要十分謹慎,如此方能在安全有效之前提 下達到良好的疼痛控制。 |
| 英文摘要 | Cancer breakthrough pain is defined as the pain that occurs despite regularly scheduled pain medication use. The clinical features of breakthrough pain include sudden onset, severe intensity and short duration. Depending on the nature of breakthrough pain, opioid analgesics are the first choice for this kind of pain management. In Taiwan, fentanyl buccal film (Painkyl) is the only product marketed to treat cancer breakthrough pain. In addition, oral oxycodone short-acting tablet (OxyNorm) is also licensed and soon launched in Taiwan. Because opioid analgesics efficacy had considerable inter-patient variation, it should be cautious of dosing and dose adjustment individualized according to response and adverse reactions. |
本系統中英文摘要資訊取自各篇刊載內容。